Literature DB >> 10646667

Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis.

J H Risse1, F Grünwald, H Bender, H Schüller, D Van Roost, H J Biersack.   

Abstract

We present a patient with thyroid cancer and hypopituitarism who required recombinant human thyrotropin (rhTSH) for 131I scanning with respect to subsequent therapy. The thyroid cancer had been unknown until central neurological symptoms developed, leading to the diagnosis of a huge metastasis to the sella that was the only manifestation of metastatic spread. The failure to generate endogenous thyrotropin (TSH) was overcome by the use of rhTSH for performing a 131I test. Unfortunately, the 131I uptake was not sufficient for therapy. This subject is the first reported case who required the application of rhTSH due to a single thyroid cancer metastasis in the sella region with secondary failure to generate endogenous TSH.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10646667     DOI: 10.1089/thy.1999.9.1253

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  3 in total

1.  Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Thyroid       Date:  2012-02-07       Impact factor: 6.568

2.  The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production.

Authors:  M Luster; W Reinhardt; C Korber; M Lassmann; H Haenscheid; U Michalowski; J Rendl; E Eising; K Mann; C Reiners
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

Review 3.  Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.

Authors:  Joanna Klubo-Gwiezdzinska; Kenneth D Burman; Douglas Van Nostrand; Mihriye Mete; Jacqueline Jonklaas; Leonard Wartofsky
Journal:  Endocr Pract       Date:  2013 Jan-Feb       Impact factor: 3.443

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.